Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
CC transcript
Appointed CFO
Quarterly results
Director comp.
Director departure
Appointed director
MICROMET, INC. (MITI) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/08/2011 8-K Form 8-K - Current report
08/04/2011 8-K Form 8-K - Current report
05/10/2011 8-K Quarterly results
Docs: "Micromet Reports First Quarter 2011 Financial Results and Highlights Near-Term Milestones -Data from Phase 2 clinical trial of blinatumomab in patients with relapsed/refractory ALL accepted for presentation at EHA Annual Congress in June -Hagop Kantarjian, M.D., Chairman and Professor, Department of Leukemia, MD Anderson to participate in conference call scheduled for today at 8:30 AM ET"
03/03/2011 8-K Form 8-K - Current report
11/09/2010 8-K Form 8-K - Current report
08/05/2010 8-K Form 8-K - Current report
05/05/2010 8-K Quarterly results
Docs: "Micromet Reports First Quarter 2010 Financial Results"
03/04/2010 8-K Quarterly results
Docs: "Micromet Reports Fourth Quarter and Full Year 2009 Financial Results"
11/05/2009 8-K Quarterly results
Docs: "Micromet, Inc. Reports Third Quarter 2009 Financial Results"
08/06/2009 8-K Form 8-K - Current report
05/06/2009 8-K Form 8-K -- Current report
03/12/2009 8-K Form 8-K -- Current report
11/06/2008 8-K Quarterly results
Docs: "Micromet, Inc. Reports Third Quarter 2008 Financial Results BETHESDA, MD, November 6, 2008 -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the third quarter and nine months ended September 30, 2008."
08/07/2008 8-K Quarterly results
Docs: "Micromet, Inc. Reports Second Quarter 2008 Financial Results BETHESDA, MD, August 7, 2008"
05/08/2008 8-K Quarterly results
Docs: "Micromet, Inc. Reports First Quarter 2008 Financial Results Bethesda, MD, May 8, 2008"
03/13/2008 8-K Quarterly results
Docs: "Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results Bethesda, MD, March 13, 2008"
11/08/2007 8-K Quarterly results
Docs: "Micromet, Inc. Reports Third Quarter 2007 Financial Results Bethesda, MD —November 8, 2007"
08/08/2007 8-K Quarterly results
Docs: "Micromet, Inc. Reports Second Quarter 2007 Financial Results Bethesda, MD - August 8, 2007"
05/09/2007 8-K Quarterly results
Docs: "2007 Outlook: — Micromet and its partner MedImmune plan to initiate a first clinical trial with our BiTE molecule targeting CD19, MT103/MEDI-538, in non-Hodgkins lymphoma patients in the U.S. and a phase 2 clinical trial in acute lymphatic leukemia in Europe. — Micromet and its partner Merck Serono are continuing their ongoing phase 1b trial in metastatic breast cancer with adecatumumab in combination with docetaxel and are preparing to initiate a phase 1 clinical trial to test adecatumumab in other solid tumors. — Micromet and its partner Merck Serono expect to release additional data from their phase 2a clinical trials at the 2007 Annual Meeting of the American Society of Clinical Oncology . — Micromet plans to advance its preclinical development program for our BiTE molecule targeting E..."
03/20/2007 8-K Quarterly results
Docs: "2007 Outlook: — Micromet and its partner MedImmune plan to initiate a first clinical trial with MT103/MEDI-538 in non-Hodgkins lymphoma patients in the U.S. and a phase 2 clinical trial in acute lymphatic leukemia in Europe. — Micromet and its partner Merck Serono will continue their ongoing phase 1b trial in metastatic breast cancer with adecatumumab in combination with docetaxel and are planning to initiate a phase 1 clinical trial to test adecatumumab in other solid tumors. — Micromet plans to advance its preclinical development program for MT110 towards an IND/IMPD filing in 2007, and is evaluating strategic corporate collaborations with this program. — Micromet and its partner TRACON Pharmaceuticals plan to initiate a phase 1 clinical trial for D93 in the second half of 2007. — Microm..."
11/13/2006 8-K Quarterly results
Docs: "2006 Outlook - Micromet expects to announce updated phase 1 clinical trial data for MT103/MEDI-538 in the treatment of patients with non-Hodgkin's lymphoma at an oral presentation at the American Society of Hematology 48 th Annual Meeting and Exposition on December 11, 2006 in Orlando, FL. - Micromet expects to present data on a phase 2a clinical trial testing the activity of adecatumumab in metastatic breast cancer at the San Antonio Breast Cancer Symposium on December 14, 2006 through December 17, 2006. 4 - Micromet plans to advance its preclinical development program for MT110, and is evaluating strategic corporate collaborations with this program. In addition, Micromet is continuing its outlicensing activities with respect to D93, MT203 and MT204. Further, Micromet intends to continue ..."
08/14/2006 8-K Quarterly results
Docs: "Micromet, Inc. reports second quarter 2006 financial results"
03/15/2006 8-K Quarterly results
Docs: "CANCERVAX CORPORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2005 FINANCIAL RESULTS"
11/07/2005 8-K Quarterly results
Docs: "CANCERVAX CORPORATION REPORTS THIRD QUARTER 2005 FINANCIAL RESULTS"
08/08/2005 8-K Quarterly results
Docs: "CANCERVAX CORPORATION REPORTS SECOND QUARTER 2005 FINANCIAL RESULTS"
05/05/2005 8-K Quarterly results
Docs: "CANCERVAX CORPORATION REPORTS FIRST QUARTER 2005 FINANCIAL RESULTS"
02/17/2005 8-K Quarterly results
Docs: "CANCERVAX CORPORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2004 FINANCIAL RESULTS"
11/10/2004 8-K Quarterly results
Docs: "REARDON CANCERVAX CORPORATION SENIOR DIRECTOR, INVESTOR RELATIONS"
08/11/2004 8-K Quarterly results
Docs: "REARDON JULIE AMES CANCERVAX CORPORATION CANCERVAX CORPORATION SENIOR DIRECTOR, INVESTOR RELATIONS DIRECTOR, CORPORATE COMMUNICATIONS"
05/13/2004 8-K Quarterly results
Docs: "JULIE AMES PAM LORD CANCERVAX CORPORATION ATKINS"
03/02/2004 8-K Quarterly results
Docs: "CANCERVAX CORPORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2003 FINANCIAL RESULTS"
12/11/2003 8-K Quarterly results
Docs: "CANCERVAX CORPORATION REPORTS THIRD QUARTER 2003 FINANCIAL RESULTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy